Physician profile

Katie Ann Gresham

Family · Evans, GA

NPI 1003589631

$10,452.35

in general payments reported to CMS, 2019-2025

45 companies · $2,428 in 2025

The $2,428 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$6,696.18

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Mannkind Corporation $1,681.56 2022-2023 Afrezza
Lilly USA, LLC $1,028.37 2021-2025 Mounjaro, Jardiance, Zepbound
Bayer Healthcare Pharmaceuticals INC. $735.65 2021-2025
Novo Nordisk INC $700.36 2021-2025 Ozempic, Rybelsus, Wegovy
Corcept Therapeutics $565.40 2021-2025 Korlym
Amgen INC. $528.04 2023-2025 Tepezza, Evenity, Prolia
Dexcom, INC. $489.63 2021-2025 Dexcom G6 Transmitter
Boehringer Ingelheim Pharmaceuticals, INC. $449.43 2022-2025 Jardiance
Xeris Pharmaceuticals, INC. $430.83 2021-2025 Gvoke Hypopen, Recorlev
Sanofi-Aventis U.S. LLC $416.34 2023-2025
Medtronic, INC. $408.48 2022-2025 Minimed 780g
Antares Pharma, INC. $382.04 2021-2025 Xyosted, Nocdurna, Tlando
Tandem Diabetes Care, INC. $337.15 2023-2025 T:Slim X2 Insulin Pump With Control-Iq
Ibsa Pharma INC. $323.51 2022-2025 Tirosint, Tirosint, Licart
Abbvie INC. $240.27 2022-2023
Show all 45 companies
CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals LP $233.99 2021-2022
Insulet Corporation $147.73 2023-2024 Omnipod
Novartis Pharmaceuticals Corporation $146.50 2021-2024
Cequr Corporation $134.66 2022-2025 Cequr Simplicity
Halozyme INC $116.78 2023
Ascendis Pharma Endocrinology INC $116.58 2025 Yorvipath
Amneal Pharmaceuticals LLC $81.02 2021-2024 Unithroid
Madrigal Pharmaceuticals $67.09 2025 Rezdiffra
Amryt Pharma Holdings LTD $57.98 2022-2023 Mycapssa
Zealand Pharma US, INC. $57.39 2022
Kyowa Kirin, INC. $51.42 2024-2025 Crysvita
Ultragenyx Pharmaceutical INC. $51.42 2022-2023
Ascensia Diabetes Care US INC. $45.76 2023
Horizon Therapeutics Plc $40.82 2023 Tepezza
Glaxosmithkline, LLC. $39.26 2025 Shingrix, Arexvy
Sequel Med Tech, LLC $38.41 2025 Twiist
Abbott Laboratories $35.81 2025
Lifescan, INC. $30.02 2021-2022
Sanofi US Services INC. $25.53 2024
Roche Diabetes Care, INC. $24.01 2023 Accu-Chek Guide Me
Amarin Pharma, INC. $23.40 2021
Embecta Corp. $22.27 2023 Bd Nano 2nd Gen Pen Needle
Radius Health, INC. $21.59 2025
Recordati_rare_diseases_inc. $21.53 2022
Eusa Pharma (US) LLC $21.53 2022
Becton, Dickinson and Company $20.32 2022
Azurity Pharmaceuticals, INC. $18.36 2023 Adthyza
Biohaven Pharmaceuticals, INC. $14.87 2021
Nevro Corp. $14.83 2023 Senza
Inspire Medical Systems, INC. $14.41 2025 Inspire

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Katie Ann Gresham

$10,452.35

in general payments reported 2019-2025

Years
2021-2025
Top company
Mannkind Corporation
Context
The $2,428 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).

https://glasscript.com/doctor/10964647/katie-ann-gresham

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.